Literature DB >> 9516110

Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

G S Ogg1, X Jin, S Bonhoeffer, P R Dunbar, M A Nowak, S Monard, J P Segal, Y Cao, S L Rowland-Jones, V Cerundolo, A Hurley, M Markowitz, D D Ho, D F Nixon, A J McMichael.   

Abstract

Although cytotoxic T lymphocytes (CTLs) are thought to be involved in the control of human immunodeficiency virus-type 1 (HIV-1) infection, it has not been possible to demonstrate a direct relation between CTL activity and plasma RNA viral load. Human leukocyte antigen-peptide tetrameric complexes offer a specific means to directly quantitate circulating CTLs ex vivo. With the use of the tetrameric complexes, a significant inverse correlation was observed between HIV-specific CTL frequency and plasma RNA viral load. In contrast, no significant association was detected between the clearance rate of productively infected cells and frequency of HIV-specific CTLs. These data are consistent with a significant role for HIV-specific CTLs in the control of HIV infection and suggest a considerable cytopathic effect of the virus in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516110     DOI: 10.1126/science.279.5359.2103

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  410 in total

1.  Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Authors:  G S Ogg; S Kostense; M R Klein; S Jurriaans; D Hamann; A J McMichael; F Miedema
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Specific therapy regimes could lead to long-term immunological control of HIV.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

3.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

4.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

6.  The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule.

Authors:  M Furchner; A L Erickson; T Allen; D I Watkins; A Sette; P R Johnson; C M Walker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

7.  The arrival of HLA class II tetramers.

Authors:  A J McMichael; A Kelleher
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

8.  Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease.

Authors:  R Salerno-Gonçalves; W Lu; J M Andrieu
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.

Authors:  P J Goulder; C Brander; K Annamalai; N Mngqundaniso; U Govender; Y Tang; S He; K E Hartman; C A O'Callaghan; G S Ogg; M A Altfeld; E S Rosenberg; H Cao; S A Kalams; M Hammond; M Bunce; S I Pelton; S A Burchett; K McIntosh; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 10.  Proving HIV-1 immunity: new tools offer new opportunities.

Authors:  L J Picker
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.